DTome: a web-based tool for drug-target interactome construction by Sun, Jingchun et al.
PROCEEDINGS Open Access
DTome: a web-based tool for drug-target
interactome construction
Jingchun Sun
1,2, Yonghui Wu
1, Hua Xu
1, Zhongming Zhao
1,2,3,4*
From IEEE International Conference on Bioinformatics and Biomedicine 2011
Atlanta, GA, USA. 12-15 November 2011
Abstract
Background: Understanding drug bioactivities is crucial for early-stage drug discovery, toxicology studies and
clinical trials. Network pharmacology is a promising approach to better understand the molecular mechanisms of
drug bioactivities. With a dramatic increase of rich data sources that document drugs’ structural, chemical, and
biological activities, it is necessary to develop an automated tool to construct a drug-target network for candidate
drugs, thus facilitating the drug discovery process.
Results: We designed a computational workflow to construct drug-target networks from different knowledge
bases including DrugBank, PharmGKB, and the PINA database. To automatically implement the workflow, we
created a web-based tool called DTome (Drug-Target interactome tool), which is comprised of a database schema
and a user-friendly web interface. The DTome tool utilizes web-based queries to search candidate drugs and then
construct a DTome network by extracting and integrating four types of interactions. The four types are adverse
drug interactions, drug-target interactions, drug-gene associations, and target-/gene-protein interactions.
Additionally, we provided a detailed network analysis and visualization process to illustrate how to analyze and
interpret the DTome network. The DTome tool is publicly available at http://bioinfo.mc.vanderbilt.edu/DTome.
Conclusions: As demonstrated with the antipsychotic drug clozapine, the DTome tool was effective and promising
for the investigation of relationships among drugs, adverse interaction drugs, drug primary targets, drug-associated
genes, and proteins directly interacting with targets or genes. The resultant DTome network provides researchers
with direct insights into their interest drug(s), such as the molecular mechanisms of drug actions. We believe such
a tool can facilitate identification of drug targets and drug adverse interactions.
Background
Currently, the discovery of novel drug candidates is
faced with several serious problems, such as a decreased
success rate [1] and an increase of the time and expense
required [2]. Most often, a limited understanding of the
underlying biological mechanisms that cause lower effi-
cacy or adverse side effects leads to these drug discovery
issues. Drug efficacy can be affected by the complexity
of biological networks, of which targets are only a part;
whereas adverse side effects of a drug may be caused by
unwanted cross-reactivity with other biologically
relevant targets [3,4]. To address these issues, it is vital
to obtain a thorough understanding of biological net-
works, disease-related pathways, and drug-altered com-
plex cellular processes in patients.
Network-based approaches have proved to be one
effective means of organizing high-dimensional biology
datasets and extract meaningful information [5,6]. Given
the complex multivariate processes and advances in
pharmacogenomic research, a theoretical foundation for
network pharmacology has been proposed [7] and suc-
cessfully applied to the field of pharmacology [8]. Net-
work pharmacology is defined as a network-centric view
of drug actions by mapping drug-target networks onto
biological networks, which provides new insights into
the role of polypharmacology in drug actions [9].
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applied to numerous areas in pharmacology, including
novel target prediction for known drugs [10-12], identi-
fication of drug repositioning and combination [13-15],
and inference of potential drug-disease associations [16].
As these network-based approaches become more and
more effective, it is necessary to develop an automated
tool to integrate drugs with biological molecules in a
network context.
This paper presents a web-based tool that automati-
cally constructs a DTome network for a given drug or
set of drugs in order to further explore the molecular
mechanisms of drug actions. Considering that protein-
protein interactions (PPIs) contain information of the
inherent combinatorial complexity of cellular systems,
we overlaid the drug targets and drug-associated genes
into human PPIs to recruit their directly interacting pro-
teins as potential off-targets. This tool integrated drugs,
drug primary targets, drug-associated genes, and target/
gene functional associated proteins into a network. We
demonstrated the utility of the tool by constructing a
DTome network for drug clozapine. To the best of our
knowledge, this is the first computational workflow to
integrate drug information with PPIs, which may facili-
tate a better understanding of the molecular mechan-
isms of drug actions for the identification of new drug
targets and the prediction of effective drug combinations
and drug adverse events.
Materials and methods
Dataset preparation
In this study, a DTome network was designed to
include three types of nodes and four types of rela-
tionships. The three types of nodes referred to drugs,
proteins and genes. Drugs included the candidate
drugs and other drugs having adverse interactions
with those candidate drugs. The proteins included
drug primary protein targets and other proteins that
interact directly with targets/genes. The drug primary
targets were extracted from DrugBank database
[17-19]. Other proteins that interact directly with tar-
gets/genes were extracted from human PPI data from
the PINA (Protein Interaction Network Analysis) data-
base [20]. The drug-associated genes referred to genes
with known pharmacokinetic (PK) and pharmacody-
namic (PD) evidence extracted from PharmGKB (The
Pharmacogenomics Knowledge Base) database [21].
The four types of relationships included drug-drug
interactions, drug-target interactions, drug-gene asso-
ciations, and target-/gene-protein interactions. The
drug-drug interactions were directly compiled from
the field of “Drug Interactions” in DrugBank, which
indicated that two drugs are known to interact, inter-
fere or cause adverse reactions when they are arranged
together. An interaction between a given drug and one
of its primary targets was assigned. Similarly, an asso-
ciation between a given drug and one of its associated
genes was defined based on the evidence extracted
from PharmGKB. The interactions between a target/
gene and other proteins were retrieved from human
PPI data.
As above mentioned, we mainly utilized data from
three databases: DrugBank, PharmGKB, and PINA.
DrugBank is a freely available online database that com-
bines detailed drug data with comprehensive drug-target
and drug-action information. We utilized DrugBank
XML file (version 3.0) downloaded on June 2011 from
the DrugBank website [22]. For each drug, we extracted
“Drug Interaction” and “Target” data to obtain adverse
drug interactions and drug primary targets. In this
study, we used the DrugBank drug IDs and drug names
to represent drugs and the unique UniProtKB accession
numbers (ACs) to represent protein targets.
PharmGKB is another knowledge base database that
captures the information about drugs, diseases/pheno-
types and genes involved in PK and PD. From this data-
base, we extracted the genes with known PK/PD
evidence, which were defined as drug-associated genes.
To map these drug-associated genes to drugs from
DrugBank, we first directly utilized the Drug External
Links files from DrugBank to map PharmGKB drugs.
Then, we transferred the unmatched drug names in the
DrugBank or PharmGKB into drug generic names using
MedEx, an automated medication extraction system for
drugs [23], and then manually checked them.
The third database we used, PINA, is an integrated
platform of PPI data extracted from six public databases:
IntAct [24], MINT [25], BioGRID [26], DIP [27], HPRD
[28] and MIPS/MPact [29]. PINA includes self-interac-
tions, interactions predicted by computational methods,
and interactions between human proteins and proteins
from other species. For the purpose of this study, we
f i r s td o w n l o a d e dd a t af r o mt h eP I N Aw e b s i t e( J u n e ,
2011) and then filtered the data by requiring PPIs to
have experimental evidence, removing redundancy and
self-interactions as well as interactions involving pro-
teins from other species. This dataset and its process
have been found useful in our many network-based pro-
jects [30,31].
To clarify and create consistency among the down-
loaded datasets, we used Entrez gene symbols to repre-
sent genes and proteins. The UniProtKB ACs were
transferred to gene symbols via two steps: 1) mapping
UniProtKB ACs to Entrez gene IDs by an ID Mapping
tool in UniProt database [32]; 2) mapping gene IDs to
gene symbols according to the annotation file down-
loaded from the NCBI human reference genome Entrez
Gene [33].
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We extracted drug information from the above three
databases and organized all the data into an open source
MySQL database management system to facilitate a
cross-database search. Each data set was saved in the
MySQL database as tables that store specific information,
whereas primary keys (e.g., DrugBank ID, GeneBank ID
and PharmGKB ID) were used extensively for relational
links. The online interface was implemented in PHP and
JavaScript, and hosted on a Linux Apache web server.
Network generation and analysis
Through its search function, the DTome tool utilizes
user-specified keywords to provide a candidate drug or
a list of drugs and generate four types of relationships.
Then, it merges these relationships to form a DTome
network, which could be further analyzed and visualized
using the Cytoscape software (version 2.8.0) [34] or
other network analysis tools.
To analyze a DTome network, in the example of cloza-
pine, we integrated multiple network characteristics to
identify critical targets and drug-bioactive modules.
Those network characteristics included degree, degree
distribution, hub, and network module. The degree of a
node is the most elementary characteristic in a network,
which is measured by the number of links of the node. If
the degree distribution of one network follows a power
law, the network would have only a small portion of
nodes with a large number of links (i.e., hubs) [35]. Hubs
in the biological network are more likely to be essential
genes, which play important roles in maintaining the
overall connectivity of the network [36,37]. To determine
the hubs in the network, we first calculated the degree
for each node in the DTome network and then plotted
the degree distribution of all nodes. Based on the degree
distribution, we determined the point where the distribu-
tion began to plateau. The nodes with a degree higher
than the point are hubs that include drugs and targets.
For network module analyses, we grouped the involved
proteins into four classes according to clozapine-specific
network topology. For the complex drug-target network,
we recommend performing cluster analysis by applying
the software cFinder, which can find and visualize over-
lapping dense groups of nodes in a network [38].
Drug classification and gene set enrichment analysis
To examine the classification characteristics of drugs
involved in the DTome network, we grouped them
using the Anatomical Therapeutic Chemical (ATC) clas-
sification system [39]. The ATC system is used for the
drug classification, which is controlled by the WHO
Collaborating Centre for Drug Statistics Methodology.
The system divides active drugs into five different levels
according to the organ or system on which they act
and/or their therapeutic and chemical characteristics.
The first level of the ATC code has fourteen main
groups, i.e. the anatomical main groups. And each
group is represented by one letter. For example, N
represents nervous system. In the case of clozapine, we
utilized the third level of the code, which indicates the
therapeutic/pharmacological subgroup.
To assess if proteins involved in the DTome network
have functional features, we performed the KEGG
(Kyoto Encyclopedia of Genes and Genomes) pathway
enrichment analysis implemented in WebGestalt (WEB-
based GEne SeT AnaLysis Toolkit) [40]. We selected
pathways with an adjusted P-value less than 0.01, calcu-
lated first using the hypergeometric test and followed by
the Benjamini-Hochberg method [41].
Results
Overview of the DTome tool
As illustrated in Figure 1, the DTome tool provides a
computational workflow to integrate candidate drugs
with their adverse drug interactions, primary targets, and
associated genes in the context of human PPIs. The
workflow includes three main steps: dataset preparation
and database construction, generation of user-specified
data and network, and network analysis and visualization.
The first step focused on dataset preparation and
database construction based on three databases (Drug-
Bank, PharmGKB, and PINA). Figure 2 shows the
detailed database design. The database included 6,796
drugs with unique DrugBank IDs and drug names, 3,848
unique primary targets with gene symbols, 10,931
unique adverse drug interactions, and 73,194 PPIs
among 11,656 proteins with experimental evidence.
From the Drug External Link files downloaded from
DrugBank, 1,135 DrugBank drug IDs were matched with
PharmGKB drug IDs. We further matched 433 drugs by
transferring the drug names from the DrugBank and
PharmGKB to generic names using the MedEx system.
Thus, a total of 1,568 drugs were mapped to each other.
After the creation of the database, a candidate drug or
a list of candidate drugs could be searched within the
database through four options of the individual or joint
inquires. The four options are “Drug Name”, “Category”,
“Group”,a n d“Indication”,w h i c hw e r ea d o p t e df r o m
DrugBank. “Drug Name” is the standard name of a drug
as provided by the drug manufacturer. “Category” is the
therapeutic or general category of a drug, such as antic-
onvulsant, antibacterial, and so on. “Group” indicates a
drug’s status, which can be one or more status of the
following: “Approved”, “Experimental”, “Nutraceutical”,
“Illicit”,a n d / o r“Withdrawn”. “Indication” is the drug-
associated disease. The DTome tool provides drug detail
information in the above options for further examina-
tion to determine if they are truly candidate drugs. This
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data integration, and further analyses.
From the candidate drug(s), the DTome tool provides
an engine to extract four relationships between candi-
date drug(s) and related molecules mentioned previously
(see Materials and Methods). Then, the DTome tool
integrates these relationships to form a DTome network
and stores it in a text file, which can be downloaded for
further network analysis and visualization.
Web interface
We developed a user-friendly web interface for the
DTome tool, which allows users to refine searches
based on four options individually and jointly (Figure
Figure 1 Overview of DTome: a web-based tool for drug-target interactome construction and analysis. The DTome network is designed
to include three types of nodes (drug, protein and gene) and four types of relationship (adverse drug interaction, drug-target interaction, drug-
gene association and target-/gene-protein interaction). The workflow includes three main steps. A) Data preparation and database construction.
This step includes parsing the data from multiple databases and creation of a database. B) Generation of user-specified data and network. The
user-specified data include a candidate drug or a list of drugs and four types of interactions. After merging the interactions, a DTome network is
formed. C) Network analysis and visualization by the Cytoscape software. PINA: Protein Interaction Network Analysis.
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candidate drug using a whole-word search or a list of
potential drugs using a partial-word search. In the
“Category” option, users can obtain a list of drugs
using a keyword of a therapeutic or general category
such as “antipsychotic”, “anticonvulsant”,o r“antibac-
terial”.I nt h e“Group” option, users can obtain a list of
drugs using a keyword for drug approval status men-
tioned previously. In the “Indication” option, users can
input a disease name and then obtain a list of drugs
that might be used to treat the disease. Additionally,
the interface also provides a combinatorial search of
above four options. After a keyword search, the output
page provides the number of drugs matching users’
requirements and a summary table (Figure 3B). For
each drug, the table provides DrugBank ID, drug
name, approval status, category, number of drug-drug
interactions, number of targets, number of associated
genes, and indication information. By manually check-
ing them, users can select the candidate drug(s) for
further analysis.
After users determine the candidate drug(s), the
DTome tool provides several data extraction options.
For each data extraction option, the tool provides a sin-
gle-system interface to output the corresponding
summary and a results table, i.e., “Get DDI” for drug-
drug interactions (Figure 3C), “Get Target” for drug-tar-
get interactions (Figure 3D), and “Get Related” for drug-
gene associations (Figure 3E). Note that target-/gene-
protein interactions are obtained using the “Get PPI”
option from the output page of drug-target interactions
or drug-associated genes (Figure 3F). For example,
besides the downloadable drug-drug interaction table,
t h eo u t p u tp a g eo f“Get DDI” provides the number of
drug-drug interactions, the number of drugs matched
the users’ requirement, and the number of the drugs
having interactions with required drugs. These summa-
ries and detailed interactions are useful for users to
further examine the relationship between candidate
drugs and relevant molecules and choose the interac-
tions for further network construction. From the “Get
Network” option, the users can select the interactions
that they are interested in and then obtain a DTome
network (Figure 3G).
Application
To demonstrate the usefulness of the DTome tool, we
constructed a DTome network for clozapine as an
example case. The procedure for a list of candidate
drugs is similar to that for an individual drug.
Figure 2 Database schema.D B :D r u g B a n k .G K B :P h a r m G K B .D D I :d r u g - d r u gi n t e r a c tion. AC: UniProtKB accessionn u m b e r .A T C :A n a t o m i c a l
Therapeutic Chemical classification system. P: primary key. N: not_NULL. F: foreign key. VARCHAR denotes “variable-length string” type in MySQL.
The number in brackets denotes the maximum length of this field.
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treat the symptoms of schizophrenia patient who do not
respond to other medications [42,43]. After searching
the database using “clozapine” in the “Drug Name”
option, a summary table and several data extraction
options mentioned previously appeared in the search
output page. The summary table showed that clozapine
had 54 drug-drug interactions, 26 primary targets, and
51 associated genes. After checking the select box fol-
lowing the drug name, the tool extracted all relation-
ships for clozapine. By clicking “Get Network” option
and selecting all data sources, we obtained a clozapine-
target network. The network included 517 edges and
406 unique nodes. Among these nodes, 55 were drugs
including clozapine and 54 other drugs having adverse
interactions with clozapine, 26 were primary targets, 51
were associated genes and 292 were proteins with direct
interactions with targets or genes (Figure 4A). There
were 16 genes that existed in both primary targets and
associated genes; they were ADRA1A, ADRA2A,
CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1,
DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C, HTR3A,
and HTR6.
Next, we noticed that the degree distribution of all
nodes was strongly right-skewed as shown in Figure 4B,
generated by NetworkAnalyzer tool, a Cytoscape net-
work analysis plugin [44]. Thus, most nodes in this net-
work had low degree while only a few nodes had higher
connections, such as DRD2, DTNBP1, HTR2A, RGS2,
SREBF1, and SREBF2.
To examine the classification of drugs that had
adverse interactions with clozapine, we grouped them
based on ATC classification system. Clozapine is an
antipsychotic drug (N05A).Among the 54 drugs, 41
(75.93%) belonge to the category “Nervous system” and
6 (11.11%) belong to “Antiinfective for systemic use”
(Figure 4C). Among the 41 drugs, 11 belong to anxioly-
tic drug (N05B), 9 belong to hypnotic and sedative
drugs (N05C), 7 belong to antiepileptic drugs (N03A),
and 5 belong to antidepressants (N06A).
To further examine the interactions among targets,
associated genes and other proteins from PPIs, we
removed the drug nodes with the exception of clozapine
node and the nodes with only one link. Overall, the sim-
plified network formed three clusters, as shown in the
Figure 4D. According to the clustering visualization in
Figure 3 DTome web interface. A) Drug search page. B) Drug search output. C) Drug-drug interaction (DDI) output. D) Drug-target output. E)
Drug-associated gene output. F) Target-protein output. G) DTome network output.
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four protein clusters and one drug cluster). To assess
functional features of these groups, we performed the
KEGG pathway enrichment analysis for four protein
clusters. All groups showed high functional homogeneity
with a Benjamini-Hochberg adjusted P-value < 0.01. The
top 5 enriched KEGG pathways for each group were
labelled in Figure 5. The 98 genes in group 1 mainly
corresponded to the significant pathways associated with
cancer and signalling pathways. Among the genes, only
two genes, SREBF1 and SREBF2,w e r ec l o z a p i n e - a s s o -
ciated genes. They encode sterol regulatory element
binding transcription factors (TFs), which are reportedly
associated with schizophrenia [45]. The 106 genes in
group 2 were enriched in the “Neuroactive ligand-recep-
tor interaction” and some signalling pathways. The 101
genes in group 3 were mainly associated with neurode-
velopment-related pathways and some of the relative
pathways. Group 2 and group 3 included most of pri-
mary targets and clozapine-associated genes. The 51
genes in group 4 were mainly linked to metabolism-
related pathways. Therefore, according to the functional
analysis, the proteins could be further categorized into
three classes: transcription-related proteins, drug-related
target/gene proteins, and metabolism-related proteins.
Overall, these classes reflect the three main molecular
layers in drug actions.
Discussion
In this study, we have developed a web-based tool to
search and integrate drug-target information to generate
a DTome network for the candidate drug(s). As demon-
strated by the construction of clozapine-target network
and the follow-up network analyses, this tool is compu-
tationally efficient and represents a promising strategy
to investigate the molecular mechanisms of drug
Figure 4 Clozapine-target interactome network and its network characteristics. A) Graphical representation of the clozapine-target
interactome network. B) Degree distribution of all nodes (drugs, targets, genes, and proteins) in the clozapine-target interactome. The Y-axis
represents the number of nodes with a specific degree. C) Graphical representation of clozapine adverse interaction drugs. According to
Anatomical Therapeutic Chemical (ATC) classification systems, the nodes in different colors represent drugs belonging to the “nervous system” at
the fourth level: N02A (light green), N03A (green), N05A (dark red), N05B (red), N05C (light red), N06A (purple), N06B (light purple), N06D (dark
purple), and N07X (yellow). Nodes in grey with brackets represent drugs related to the “antiinfective for systemic use”. Other nodes in grey
represent drugs belonging to other categories with exception of above two categories. D) Graphical representation of clozapine-target
interactions after removing the nodes with degree 1 and other drug nodes. An edge in red represents the relationship between clozapine and a
target, an edge in blue represents the relationship between clozapine and an associated gene, and an edge in green represents the interaction
between a target/gene and a protein from protein-protein interaction (PPI) data.
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in the pharmacogenetics and pharmacogenomics areas.
This study mainly utilized two major drug datasets:
DrugBank and PharmGKB and the integrative PPI data
set from the PINA database. Thus, when interpreting
these results from the datasets, one should keep in mind
that the current workflow has its own limitations,
including both drug data and human PPI data that are
incomplete and are not error-free. Since several target-
centered databases are available, such as Matador and
SuperTarget [46], and the Therapeutic Target Database
(TTD) [47], we will integrate more drug target datasets
into the system to ameliorate the effects of data limita-
tion in the future.
The network-based approach is emerging as a highly
promising method to studying massive amount of omics
data, and it has been successfully applied to numerous
human disease studies [48,49]. In this study, we imple-
mented the network pharmacy concept in a robust sys-
tem by including the direct interactors from the PPI
data into the drug-target network. This method is
simple yet effective to obtain the relationship between
the drug targets or drug-associated genes and their
interacting proteins. Analyses of the DTome network
for a specific drug or a list of drugs may allow for the
identification of new drug targets and a better under-
standing of the molecular mechanisms of drug actions.
Conclusions
In this study, we presented a computational workflow to
generate a DTome network for a given drug or a list of
drugs, and implemented the workflow through an online
drug information search and integration tool. The tool is
computationally efficient in generating and integrating
drug-drug, drug-target, drug-associated, and target-pro-
tein interactions to build a DTome network. Our
demonstration using the antipsychotic drug clozapine
shows that the output of our system provides a starting
point to further investigate the molecular mechanisms
of drug actions, thereby suggesting its usefulness in the
pharmacogenetics and pharmacogenomics research.
Figure 5 Functional analysis of proteins in clozapine-target interactome network. Based on the topological features of the clozapine-target
interactome network, the proteins involved in the network could be generally classified into 4 groups. For each group, the top 5 enriched KEGG
pathways were listed.
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